BriaCell Therapeutics Corp. (BCTX)

Market Cap	29.79M +31.3%
Revenue (ttm)	n/a
Net Income	-30.68M
EPS	-9.39
Shares Out	8.70M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	52,696
Open	3.470
Previous Close	3.410
Day's Range	3.318 - 3.640
52-Week Range	2.600 - 13.900
Beta	1.51
Analysts	n/a
Price Target	n/a
Est. Earnings	Dec 10, 2026

About BCTX

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore Co...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 16
• Stock Exchange: Nasdaq
• Ticker Symbol: BCTX
• Website: https://briacell.com

Financial Performance

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 24, 2026

Data Sources Report a data error